EADV财务官Menno de Rie教授对本次在巴黎举行的年度大会上"突破性"的参与人数（近20,000人）表示欣喜。他强调了学会的迅猛发展，会员人数在短短四年内从6,000人翻了一番多，现已超过13,000人，他认为这清楚地表明了大家对学会工作的认可。教授还指出，EADV的全球影响力正在扩大，吸引了来自欧洲以外地区，包括北美、中东和印度的皮肤科医生的浓厚兴趣和积极参与。
除了大会，Menno de Rie教授强调了EADV广泛的教育计划。这些包括组织研讨会、出版两本期刊以及制作大量播客和各种教育材料。学会的一个关键优先事项是激励和支持年轻的皮肤科医生。这是通过降低费用、提供资助以及在大会期间举办专门的教育"学校"活动来实现的，以确保该领域持续充满活力。
大会的科学议程内容广泛，有超过600名讲者参与。教授特别强调了他共同主持的一场关于突破性摘要的会议，该会议展示了有前景的新药，尤其是JAK抑制剂。他指出，这些疗法通过有效治疗以往选择有限的疾病，如化脓性汗腺炎、白癜风和斑秃，正在彻底改变皮肤病学。会议还涵盖了对特应性皮炎的广泛研究，超越了现有的度普利尤单抗等治疗方法，转向即将问世的新药，以满足患者显著的未竟需求。Menno de Rie教授对制药业的积极参与表示感谢，这使得展示令人兴奋的研发中药物成为可能，让皮肤病治疗的未来显得无比光明。
Prof. Menno de Rie, Treasurer of the European Academy of Dermatology and Venereology (EADV), expressed his delight at the "groundbreaking" number of participants—nearly 20,000—at the annual congress in Paris. He highlighted the Academy's tremendous growth, with membership more than doubling from 6,000 to over 13,000 in just four years, viewing this as a clear appreciation of the Academy's work. Prof. de Rie also noted the expanding global reach of the EADV, with significant interest and attendance from dermatologists outside Europe, including North America, the Middle East, and India.
Beyond the congress, Prof. de Rie underscored EADV's extensive educational initiatives. These include organizing symposia, publishing two journals, and producing numerous podcasts and various educational materials. A key priority for the Academy is to stimulate and support younger dermatologists. This is achieved through reduced fees, grants, and dedicated educational "school" activities during the congress, ensuring the continued vitality of the field.
The scientific program in Paris was extensive, featuring over 600 speakers. Prof. de Rie specifically highlighted a session he co-chaired on groundbreaking abstracts, which showcased promising new drugs, particularly JAK inhibitors. These therapies, he noted, are revolutionizing dermatology by effectively treating diseases previously with limited options, such as hidradenitis suppurativa, vitiligo, and alopecia areata. The session also covered extensive research on atopic dermatitis, moving beyond existing treatments like Dupilumab to new drugs on the horizon, addressing a significant unmet patient need. Prof. de Rie expressed gratitude for the strong participation of the pharmaceutical industry, which allows for the presentation of exciting pipeline drugs, making the future of dermatology treatment look very bright.
